Azacitidine is an antineoplastic agent believed to exert its effects by multiple mechanisms, including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA.
The cytotoxic effects are thought to be as a result of DNA, RNA and protein synthesis inhibition as well as the activation of DNA damage pathways.
It is recommended that patients be treated for a minimum of six cycles and treatment should be continued as long as the patient continues to benefit or until disease progression. Each cycle consists of 28 days and patients should be monitored for haematologic response/toxicity and renal toxicities.
Further information: Celgene